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Abstract
Background: This study was designed to investigate the prevalence and correlates of depression in Myotonic 
dystrophy type 1 (DM1).
Methods: Thirty-one patients with DM1 and 47 subjects in a clinical contrast group, consisting of other neuromuscular 
disorders, including Spinal muscular atrophy, Limb girdle muscle atrophy and Facioscapulohumeral dystrophy, 
completed Beck Depression Inventory (BDI). We aimed to establish whether different factors associated with DM1 
correlated with ratings in the BDI.
Results: Signs of a clinical depression were prevalent in 32% of the patients with DM1, which was comparable with 
ratings in the clinical contrast group. The depressive condition was mild to moderate in both groups. In DM1, a longer 
duration of clinical symptoms was associated with lower scores on the BDI and higher educational levels were 
correlated with higher scores on depression. We also found a negative association with brain white matter lesions.
Conclusions: Findings indicate significantly more DM1 patients than normative collectives showing signs of a clinical 
depression. The depressive condition is however mild to moderate and data indicate that the need for intervention is 
at hand preferentially early during the disease process.
Background
Depression is an important health issue because of its
high lifetime prevalence and association with substantial
disability [1]. An increased risk of having major depres-
sion is associated with chronic disease, neurological and
neuromuscular disorder and a comorbid state of depres-
sion has been found to incrementally worsen health [1-3].
Without treatment, depression has a tendency to assume
a chronic course, be recurrent and over time to be associ-
ated with increasing disability [1]. Consequently, the pos-
sible comorbidity of depression with chronic disease is
important to acknowledge.
Myotonic dystrophy type 1 (DM1) is a progressive,
dominantly inherited, multisystem disease caused by an
expanded and unstable trinucleotide CTG repeat local-
ized to the 3' untranslated region of the dystrophia myo-
tonica protein kinase (DMPK) gene on chromosome
19q13.3 [4]. The expansion of CTG repeats causes muscle
wasting, myotonia, heart conduction defect, lens cata-
ract, endocrine dysfunction and brain abnormalities
through different molecular mechanisms [5]. A growing
body of evidence shows that a RNA gain-of-function
mechanism plays a major role in the disease development
but the process explaining neurocognitive dysfunction is
however more uncertain [6-8]. It is known that DM1 is a
disorder associated with neuropsychological deficits,
including reduced attention, speed, visuoconstructive
and executive abilities [9]. Accompanying brain abnor-
malities is predominant in frontal and temporal, occipital
and subcortical regions, including both cerebral atrophy
and white matter hyperintense lesions [7]. Mood and per-
sonality disorders associated with apathy and social
avoidance is recurrently seen [7,10]. Some authors have
found significantly higher prevalence of depression as
compared to healthy controls [11,12] but others have
found no indication of major depression [13-15]. Further-
more, the cause of depression in DM1 is still not clear,
where some authors have tried to explain depression as a
psychological adaptation to the disease [11] and others,
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as a direct manifestation of genetic and/or CNS abnor-
malities [13,14]. However, to date, no study has con-
firmed any significant association between depression
and clinical and/or biological parameters. The aims of
this study were to characterize and to evaluate occur-
rence of depression in patients with DM1 and to explore
clinical, genetic and neurocognitive correlates.
Methods
Subjects
Demographic and clinical data are presented in Table 1.
Sixty adult patients with genetically confirmed DM1,
associated with the Neuromuscular Centre, Sahlgrenska
University Hospital in Göteborg, were invited to partici-
pate. Inclusion criteria were: age 18-65 years and no his-
tory of major psychiatric or somatic illness, major brain
injury or alcohol misuse. Twenty-nine declined, mainly
due to non-compliance in taking part in the brain imag-
ing and CSF-measurement, leaving 31 patients with adult
onset/classical DM1. Forty-seven patients with other
neuromuscular disorders formed a clinical contrast
group. This group comprised 13 patients with spinal
muscular atrophy, 14 with limb girdle muscle atrophy and
20 with facioscapulohumeral dystrophy. In DM1 patient's
strength in handgrip was measured with the Grippit
instrument [16] and the overall muscle function was
scored using the Muscle Impairment Rating Scale (MIRS)
[17]. In both groups, Brooke's grading system of mobility
was scored [18]. All participants gave informed and writ-
ten consent and the medical ethics committee at the
Sahlgrenska Academy, Göteborg University, approved the
study.
Self-rating of depression
We used a Swedish version of Beck Depression Inventory
(BDI), a widely used 21-item standardized self-report
questionnaire measuring depression on a 4-point scale
ranging from 0 to 3 [19,20]. Proposed cut-off scores may
be interpreted as follows: 1-9, minimal depression; 10-16,
mild depression; 17-29, moderate depression; 30-63,
severe depression [20]. We also performed an item-analy-
sis on two separable factors of depression in the BDI; a
cognitive affective dimension (item 1-13) and a somatic
dimension (item 14-21) [20].
Neuropsychological assessment
All subjects participated in a neuropsychological investi-
gation comprising tests measuring verbal ability (Vocabu-
lary), verbal fluency (FAS), visual construction and
memory ability (RCFT, Block design, Picture comple-
tion), verbal memory (RAVLT), speed (Trail Making Test,
Digit symbol), attention (TMT, Digit span, Spatial span)
and executive function (Stroop, TMT, FAS and WCST).
Tests, references and procedure have been described in
earlier studies by the authors [8,9].
Brain MRI and cerebrospinal fluid examination
As to explore directly visible and indirect manifestations
of brain functioning we performed a brain MRI examina-
tion and a measurement of cerebrospinal fluid (CSF)
markers indicative of neuronal degeneration and amy-
loidogenesis.
Twenty-nine patients had MRI examinations which
were performed on a 1,0 Tesla magnet (Siemens Magne-
tom Impact, Erlangen, Germany) or a 1,5 Tesla magnet
(Siemens Symphony, Erlangen, Germany). The protocol
Table 1: Demographic and clinical description of subjects
DM1 (n = 31) Contrast group (n = 47)
Age 41.8 (9.5, 23-58) 43.5 (15.0, 18-64)
Sex 14 M, 17 F 15 M, 32 F
Education (years) 10.9 (2.2, 8-18) 10.4 (1.8, 9-15)
Age at onset 26.2 (8.7, 15-50) 17 (14.5, 0-60)
Disease duration (years) 16.8 (10.7, 3-38) 27 (16, 5-60)
CTG-repeats 578 (401, 100-2000) -
Fatigue* 25 (81%) -
MIRS** 3.6 (0.8, 1-5) -
Grip force† (Newton) 104 (48, 20-144) -
Brooke-rating†† 0.5 (1.1) 5.9 (13.9)
* Patients scoring the presence of abnormal fatigue in a self-rating procedure described in Winblad et al, 2005 [9].
** Muscular Impairment Rating Scale [17]. This score ranges from 1 (no muscular impairment) to 5 (severe proximal weakness).
† Scores on a handgrip force measurement using the Grippit instrument. Mean (SD) for healthy controls = 331 (77) Newton [16].
†† Brookes functional test and grading system, zero implies normal function and higher values indicates increasing levels of immobility [18].
Data in Table 1 is presented as mean, standard deviation and range.Winblad et al. Behavioral and Brain Functions 2010, 6:25
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consisted of a T2 and a proton density or FLAIR
sequence in axial projection. A coronal FLAIR and a sag-
ittal T2 sequence were included at the end of the study
when the MRI equipment was updated. One experienced
neuroradiologist blinded to clinical symptoms evaluated
all MR images. A rating of white matter lesions [21,22],
brain atrophy and ventricular size [23] was performed
according to procedures earlier described in Winblad et
al. 2008 [8].
T w e l v e  m l  o f  C S F  w a s  o b t a i n e d  b y  r o u t i n e  l u m b a r
puncture, centrifuged and stored in aliquots at - 80°C.
Analyses of CSF-tau levels were made using a sandwich
ELISA (Innotest hTAU-Ag, Innogenetics, Gent, Belgium)
constructed to measure both normal and phosphorylated
tau. Quantification of tau phosphorylated at threonine
181 (P-tau) was performed with a sandwich ELISA proce-
dure (Innotest Phospho-Tau (181P), Innogenetics, Gent,
Belgium). Levels of Aβ42 were done using an ELISA
(Innotest β-amyloid (1-42), Innogenetics) [24,25].
Genetic analysis
DNA was extracted from peripheral blood lymphocytes
and analysed for expansion of the CTG repeat in the
DMPK gene. The analysis was performed with PCR and
southern blot using the probe pM10M6 [26]. The size of
the CTG-expansions was assessed visually from exposed
x-ray films.
Statistical analysis
Data were analysed using SPSS base 11.5 (Chicago IL)
and are presented as median and interquartile range (IR).
Due to skewness in the data set, non-parametric statistics
were used in comparisons between groups. The Spear-
man rank correlation test was used when analysing corre-
lations between measures. Significance level was set at P
< 0.05.
Results
Results on the BDI rating showed that DM1 patients and
the clinical contrast group (CCG) scored with a median
value of 6 (IR = 5) and 7 (IR = 10), respectively. There was
no significant difference between groups. Figure 1 shows
the distribution of scores. Ratings above a cut off score
for depression set at 10 [20] were found in 10 DM1 (32%)
and 19
(40%) CCG patients. Among DM1 patients indicating
clinical depression, a mild depression was most prevalent
and signs of a moderate depression were found in a
minority of patients. The same pattern was found in the
CCG. Ratings indicating a severe depressive condition
( B D I  s c o r e  >  3 0 )  w e r e  a b s e n t  i n  b o t h  g r o u p s .  W h e n
analysing the distribution on separate items in the BDI,
high scores were found on the somatic dimension of
depression associated with fatigability, hypersomnia and
muscle weakness but also high scores on negative body
image and somatic pre-occupation. In contrast, low
scores were found on the cognitive-emotional dimension,
including suicidal ideas, sadness, pessimism, guilt, self-
dislike and punishment. A significant difference (P <
0.001) between somatic and social-cognitive dimensions
was found in both the DM1 (Z = -3.32) and the CCG (Z =
-3.55).
Disease duration correlated significantly with BDI
scores (rs = -.426, P < 0.02) (Figure 2) indicating that a
clinical depression was typically present in patients with
disease duration less than 20 years. This association was
not found in the CCG.
We did not find any difference on BDI scores when
comparing four groups of DM1 patients with different
CTG repeat expansion sizes (50-150, 151-500, 501-1000
and > 1000 repeats, respectively). No significant associa-
tion was found between BDI ratings and CSF levels of
Aβ42 and Tau. However, we found a significant difference
between groups (Z = -2.3, P < 0.02) on BDI scores when
comparing patients with white matter lesions (Median
BDI score = 6) and patients without (Median BDI score =
8.7). When analyzing the difference between four groups,
based on grading of white matter lesion load, a pattern
emerged, indicating that mild-few punctuate foci or
patchy non-confluent lesion to moderate-beginning con-
fluent loci was gradually more associated with lower BDI
scores than a condition associated with the absence of
white matter lesions. No difference was found on other
brain imaging data including the presence/absence of
atrophy, periventricular lesions and ventricular widening.
Ventricular brain ratio did not correlate with BDI scores.
Concerning neuropsychological measures, gender, age,
age of onset, MIRS score, handgrip strength or ratings of
fatigue, there was no association with BDI-scores. How-
ever a positive correlation was found between years of
education and ratings on depression (rs = .44, P < 0.02)
indicating that DM1 patients with higher education (> 11
years) also scored higher on the BDI.
Discussion
The present study identified clinical depression in 32% of
the patients with DM1. The depressive condition was
mild to moderate and comparable to ratings in a clinical
contrast group comprising other neuromuscular disor-
ders. The point prevalence of depression in normative
collectives ranges between 2-5% [27], indicating a signifi-
cantly higher prevalence of depression among DM1
patients and the CCG. When analysing single items on
t he  BDI,  a  la r g e  m a jo rit y of  pa t ie n ts  sc or ed high on a
somatic dimension and contrastingly low on cognitive-
emotional content. Consequently, few DM1 patients
meet a psychiatric criterion of depression due to lowWinblad et al. Behavioral and Brain Functions 2010, 6:25
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scores on the emotional-cognitive dimension. This rea-
sonably explains why measurement using a direct psychi-
atric evaluation (DSM-IV) [28] has not confirmed major
depression as significant in DM1 [12,13]. When compar-
ing criteria for depression [28] with DM1 specific bodily
symptoms, such as fatigue, muscle weakness and sleep
disorder, there is a considerable overlap, indicating that
high scores on the BDI were mainly associated with an
impact of the disease, rather than a psychological reac-
tion on the condition. These findings reasonably have
clinical importance, when considering that the high prev-
alence of fatigue, reduced initiative and facial weakness in
DM1, may lead to a misconception of a major depressive
condition, comparable to misjudgements done in other
neurological disorders [29].
Data showed that depression was associated with ear-
lier stages of DM1. This finding has been highlighted in
other diseases [30] but stands in sharp contrast to
assumptions postulating that the progressive nature of
the disease contribute to the depressive condition [11].
Indeed, our findings may seem contra-intuitive when
considering that DM1 is a progressive disabling disease
[11]. Findings in the present study may be explained by
patients use of instrumental coping strategies as to meet
symptoms and consequences late during the disease in
contrast with predominantly emotion-focused coping
(crisis reaction and depression) early on. Low scores on
depression, late in the disease, may also be associated
with a narrowing of life expectancies and demands as the
disease progress, leading to reduced stress and negative
emotional reactions. A large difference between expected
life circumstances and the actual life-situation might con-
tribute to signs of depression early in the course of the
disease, with closeness to an imagined life without DM1.
A discrepancy between expected and actual life circum-
stances may also contribute to the prevalence of depres-
sion among patients with higher education. Notably
however, correlations between BDI-ratings, disease dura-
tion and education were not found in the CCG, indicating
disease specific associations in DM1.
Findings in this study showed significantly lower BDI
scores in DM1 patients with white matter lesions
( W M L s )  a s  c o m p a r e d  t o  p a t i e n t s  w i t h  a n  a b s e n c e  o f
WMLs. This indicates that brain damage may actually
"protect" against depression - a finding comparable to an
association described in a recent study on the prevalence
of post-traumatic stress disorder and brain damage
among combat veterans [31]. Hypothetically, this associa-
tion may be explained by a clinical phenomenon
described in DM1: a lack of awareness of deficit [7]. A
lack of awareness may be associated with reduced levels
of depression as the disease progress, due to the fact that
Figure 1 Distribution of BDI scores of patients with DM1 and clinical contrast group patients. Description of values: 1-9 = minimal depression, 
10-16 = mild depression, 17-29 = moderate depression. Cut off value on clinical depression = 10 (20).Winblad et al. Behavioral and Brain Functions 2010, 6:25
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a reaction to the condition reasonably involves awareness
of the condition. Generally, the ability to interpret signals
from the body but also to experience deficits have been
associated with localised lesions [32]. These brain areas
mainly include the prefrontal- and parieto-temporal cor-
tex, insula and thalamus. Interestingly, when analyzing
the localisation of lesions in respect to brain areas in
DM1 we found a main localisation in corresponding
areas; central temporal and frontal areas, but also the
insula region (data not shown). We also found an associa-
tion, indicating a trend (P = 0.075) between lower BDI
scores and lesions in the temporal cortex. These associa-
tions indicate the need for further studies on lack of
awareness in DM1, including prevalence, causative fac-
tors and further consequences.
Limitations
Conclusions based on present findings are limited by sev-
eral factors. Due to used study design, i.e., the inclusion
of only patients with adult onset DM1, it is still an open
question if an onset < 10 years is associated with a higher
prevalence of depression. Furthermore, the validity of
used measurement of fatigue is reasonably limited. It is of
importance to incorporate reliable measures on both
fatigue and daytime sleepiness in future studies due to
high prevalence and possible behavioural impact in DM1
[ 3 3 ] .  A n  a n a l y s i s  o f  c o r r e l a t i o n s  b e t w e e n  m e a s u r e s  o f
depression and more sophisticated brain-imaging tech-
niques such as PET and voxel based morphometry [34]
may also reveal important associations between behav-
ioural and imaging data beyond basic findings using con-
ventional MRI.
Conclusions
This study shows a clinical depressive condition in
roughly one in three patients with DM1. This condition is
mild to moderate and mainly associated with early stages
of the disease, a higher educational level and the absence
Figure 2 Correlation between DM1 patient's scores on Beck Depression Inventory (BDI) and duration of disease (years), rs = -.426, P < 0.02.Winblad et al. Behavioral and Brain Functions 2010, 6:25
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of brain white matter lesions. This indicates an impact of
both clinical and social but also neuronal factors. Consid-
ering treatment options, our data indicate a need for
intervention preferentially early in the disease process.
Furthermore, depression in DM1 has to be understood in
the context of factors directly associated with the disease,
including apathy, reduced initiative and fatigue and rea-
sonably at first hand targeting these factors, using both
medication and proper behavioural and physical inter-
ventions [35,36].
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